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Abstract
Background: Japanese encephalitis (JE) is a flaviviral disease of public health concern in many parts of Asia. JE often occurs
in large epidemics, has a high case-fatality ratio and, among survivors, frequently causes persistent neurological sequelae
and mental disabilities. In 1997, the Vietnamese government initiated immunization campaigns targeting all children aged
1–5 years. Three doses of a locally-produced, mouse brain-derived, inactivated JE vaccine (MBV) were given. This study aims
at evaluating the effectiveness of Viet Nam’s MBV.
Methodology: A matched case-control study was conducted in Northern Viet Nam. Cases were identified through an
ongoing hospital-based surveillance. Each case was matched to four healthy controls for age, gender, and neighborhood.
The vaccination history was ascertained through JE immunization logbooks maintained at local health centers.
Principal Findings: Thirty cases and 120 controls were enrolled. The effectiveness of the JE vaccine was 92.9% [95% CI: 66.6–
98.5]. Confounding effects of other risk variables were not observed.
Conclusions: Our results strongly suggest that the locally-produced JE-MBV given to 1–5 years old Vietnamese children was
efficacious.
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Introduction
Japanese encephalitis (JE) is a mosquito-borne flaviviral disease
endemic in many regions of Asia [1]. Culex tritaeniorhynchus, the
principal mosquito vector of the JE virus (JEV), preferentially breeds
in rice fields [2,3]. Swine are potent amplifiers of the virus and
exhibit rapidly after virus transmission considerable viral loads.
Thus, Culex mosquitoes breeding in rice fields and feeding on swine,
are critical ecological factors favoring JE transmission to humans in
rural areas. Prior to the availability and introduction of vaccines, JE
was a significant cause of mortality in the northern provinces of Viet
Nam with an annual incidence of 5–15/100,000 [4].
Most JE infections (96%–99.9%) are asymptomatic or present as
a mild disease only with rather non-specific flu-like symptoms.
However, among symptomatic patients who exhibit symptoms of
encephalitis and/or serious neurologic infection, the case-fatality
ratio can be as high as 10%–30% [5,6]. Among survivors, 30% to
50% of individuals suffer from chronic, severe neuropsychiatric
disabilities [5–7]. Why only a small proportion of infected
individuals experience severe disease is not clear. Reasons may
include host genetic factors, but also virulence factors of differing
virus strains. Children younger than 15 years are at the highest risk
of infection and the incidence peaks at three to ten years of age [7].
JE infections efficiently induce protective immunity [8] and
seroprevalence studies indicate almost universal exposure to the
infection in endemic areas by adulthood [9].
Specific antiviral treatment for JE is not available [10] and care
of patients strongly depends on supportive measures. Vaccination
is the primary strategy for prevention of infection [1] and has been
shown to dramatically reduce the disease incidence in South
Korea [11,12], Japan [13], China [14,15], Thailand [15] and
Taiwan [16]. In Viet Nam, children receive three pediatric doses
(0.5 ml/dose) of a locally-produced, mouse brain-derived, inacti-
vated JE vaccine (MBV; Nakayama strain; VaBiotech, National
Institute for Hygiene and Epidemiology (NIHE), Ha Noi, Viet
Nam) with the first two doses at one year of age given at an
interval of two weeks followed by a third, booster dose one year
later. The production of the MBV in Viet Nam was initiated in
1989 and supported by technology transfer from Japan. Bridging
studies suggest that the Vietnamese MBV has an immunogenicity
similar to that of the Japanese vaccine, reaching nearly 100%
immunogenicity in children after the application of two doses [1].
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The vaccine was integrated into Viet Nam’s national Extended
Program of Immunizations (EPI) in selected districts of Ha Tay
and Hai Phong provinces in 1997.
Hospital-based surveillance of all patients presenting with an
acute encephalitis syndrome (AES) is ongoing in the Ha Tay and
Hai Phong Provincial Hospitals in the North of Viet Nam. Two
provincial hospitals in the Ha Tay Province as well as the National
Pediatric Hospital in Ha Noi are used as referral hospitals for JE
surveillance since January 1, 2004. These hospitals jointly account
for approximately 95% of all cases of acute encephalitis notified in
the Ha Tay Province. In Hai Phong province, cases are identified
through the national AES surveillance system. Cerebrospinal fluid
(CSF) is collected at admission. The presence of immunglobulin-M
(IgM) antibodies to JEV (anti-JEV) in CSF is defined as one of the
criteria for a JE diagnosis [17–19]. Initial testing of specimens is
performed at the National Pediatric Hospital Laboratory and
Laboratory of Ha Tay Preventive Medicine Center, and
confirmatory testing of all specimens was done by sending coded
samples to the Department of Virology, Armed Forces Research
Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
The objective of the present study was to assess in a case-control
design the effectiveness of this MBV JE vaccine.
Methods
Ethical clearance
The study was conducted according to ethical principles
consistent with the International Guideline for Ethical Reviews
of Epidemiologic Studies [20]. The Institutional Review Board of
the International Vaccine Institute, Seoul, Republic of Korea, and
the local ethical committee of NIHE, Ha Noi, Viet Nam approved
the study and granted ethical clearance. Vaccination status’ of
participants were assessed from vaccination records of the health
centers. During visits of the households of children that were
aimed at assessing the distances of piggeries and ricefields from the
houses, oral informed consent was obtained from parents/
guardians of cases and controls and documented in the
questionnaire. Oral consent was considered appropriate for the
study and approved by both Ethical Review Boards.
Study design
For this matched case-control study, patients with a confirmed
diagnosis of JE and younger than 15 years of age were identified
from the database of the surveillance hospitals from January 2004
to December 2007. Older children were not recruited, as they
could not have received JE vaccines through the national
immunization program.
Controls were chosen from the birth registry of all births in the
health center of the village of the case and matched for gender, age
(+/2 six months), and proximity of their house.
Only after four controls had been selected from birth registry
and agreed upon by the study team, the vaccination record books
were opened and the individual vaccination status was assessed. JE
vaccination is provided during an annual mass campaign and
vaccination records are kept at the health centers.
The houses of cases and controls were visited and as an
indicator of potential exposure to infection and the distances to
piggeries and rice fields were assessed by the study team after
obtaining oral informed consent from the adult/guardian present.
Statistics
A Student’s t-test for unequal distributions was used to compare
the age distribution of cases and controls. A chi-square test was
employed to compare cases and controls for the proportion of
males, proportion living within #50 meters of a piggery and
percent living #30 meters of rice fields. A matched conditional
logistic regression model was employed to evaluate the protective
effect of immunization. A single dependent (JE disease) and
independent variable (immunization status) was entered into the
model. Odds ratios (OR), 95% confidence intervals (CI), and p
values were calculated from model parameters. The protective
effect of immunization was assessed for residents receiving three or
more doses relative to two or less doses. Vaccine effectiveness (VE)
was calculated as VE=12OR6100 [21]. The threshold of
statistical significance was p,0.05. All statistical analyses were
performed using the Stata v 10.0 software (Stata Corp., Texas,
USA).
Results
We identified 30 laboratory-confirmed cases of JE infection and
these were matched to 120 controls. After selection of controls was
completed, it became evident that two controls were chosen who
had no information on their immunization status in the birth
registries. These two controls were excluded from the calculation
of vaccine effectiveness. As cases and controls were matched for
age and gender, no significant differences were observed between
cases and controls for these variables. Cases and controls resided
equidistantly from rice fields and piggeries (Table 1).
Only individuals who had received the full course (three doses)
of JE vaccine were considered as vaccinated; two cases and two
controls received one and two cases and six controls two doses of
Table 1. Comparison of socio-economic variables for cases
and controls.
Cases (n =30) Controls (n =120) P
Male .63* .63* 1.00{
Mean age, years (Range) 6.8 (4–13) 6.9 (3–13) 0.63{
Rice fields #50 m .37* .37* 1.00{
Piggeries #30 m .6* .58* 0.83{
{chi-square test;
{, paired t-test for unequal distribution,
*proportions.
doi:10.1371/journal.pntd.0001952.t001
Author Summary
Japanese encephalitis (JE) is a disease caused by a
flavivirus transmitted by mosquitoes. Although pigs and
wild birds are main reservoirs of the disease, it is
occasionally transmitted to humans. The majority of
infections in humans are asymptomatic. In persons
developing encephalitis, JE has a high case-fatality rate
and, among survivors, JE frequently causes persistent
neurological sequelae and mental disabilities. Therefore, it
is a public health concern in many parts of Asia and many
countries vaccinate against JE. Since 1997, children in
Vietnam are vaccinated in high risk areas and receive a
locally-produced vaccine. This study is aimed at evaluating
the effectiveness of the Vietnamese JE vaccine through a
case-control study, in which 30 cases and 120 controls
were enrolled. The effectiveness of the JE vaccine was
92.9% [95% CI: 66.6–98.5], which suggests that the locally-
produced JE vaccine given to 1–5 year old Vietnamese
children was efficacious.
Effectiveness of Japanese Encephalitis Vaccine
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JE vaccine, respectively, and were considered as not vaccinated
(Table 2).
Among the 30 laboratory-confirmed cases, the proportion of
cases vaccinated was 60.0%, compared to 86.4% among the 118
control individuals. Based on the matched analysis vaccine
effectiveness reached 92.9% [95% CI: 66.6–98.5%] (Table 2).
Discussion
Three previous trials have evaluated the effectiveness of the JE
MBV. A randomized double-blinded study conducted in northern
Thailand, using JE MBV produced in Thailand, yielded an overall
effectiveness of 91% [95% CI: 70.0–97.0] [22]. Another trial in
Taiwan evaluated a Taiwanese vaccine and revealed an effective-
ness of approximately 85% when two or more doses were
administered [23]. A case-control study in Thailand showed an
effectiveness of 94.6% in children $18 years of age [24]. The
present matched case-control study suggests that the MBV
produced in Viet Nam yields results that are similar to those of
the Thailand and Taiwan studies.
Even though the MBV has an excellent efficacy, its usage was
recently restricted after considerable safety concerns were raised.
Severe reactions such as hypersensitivity, including generalized
urticaria and angioedema, occurred at far higher rates than
observed in other routine vaccinations [25,26,27,28]. Consequent-
ly, Japan no longer recommends JE MBV vaccination [29,30] and
recently introduced a Vero cell-derived JE vaccine; other countries
are currently in the process of phasing out the MBV (e.g.,
Thailand, Sri Lanka). Nevertheless, MBV safety issues have not
led to any restrictions in its use in Viet Nam. However, Viet Nam
is currently developing its own Vero cell-derived vaccine, which is
foreseen to be available for use in 2014/2015.
The Vietnamese government has announced that it would
eliminate clinical JE by 2015. However, in contrast to poliomyelitis
virus, for which humans are the only hosts, the JE virus is enzootic
and is, therefore, unlikely to be entirely eradicated from the
environment. A recent JE surveillance study has shown that, even
in the virtual absence of manifest human disease after vaccination,
JEV is still widespread among swine [31], showing that active
transmission is perpetuated and that protective immunity of
humans through persistent vaccination is a key measure to
preventing disease in humans [13]. Therefore, controlling clinical
JE disease through vaccination would not impact on reducing or
eradicating the circulation of the virus within the vectors and
animal hosts as JE is not transmitted from person to person and JE
vaccination does probably not confer herd immunity [32].
Depending on the potency of enzootic transmission and the age-
specific risks of natural human infection, the age for primary
vaccination differs between countries. Most countries give one to
two booster doses after the initial three-dose regimen [1].
In contrast to Japan and Korea, where nation-wide changes in
lifestyle have provided additional contributions to the control of JE
[11,33], rural areas in Viet Nam have so far largely remained
agrarian. Rice paddies cover extensive geographic areas, and little
changes only have occurred in the natural environment and living
conditions. Even though the effectiveness of the vaccination
program appears to be high, an annual average incidence of 3.4/
100,000 was observed among children less than 10 years of age.
The current JE immunization program may be improved by
immunizing younger children (6–23 months of age) who are at the
highest risk of patent infection, and providing a booster dose at 3–
5 years after initial immunization with the three-dose regimen,
reducing waning immunity in immunized children [1].
An inherent problem of inactivated vaccines is that due to their
low immunogenicity, multiple vaccinations are required in order
to induce and maintain sustained levels of protective immunity.
Following the initial three doses given at immunization, the
effectiveness of the MBV declines over years [34]. Therefore, the
introduction of one or more booster doses using the adult
formulation to children at school age is recommended to ensure
protective immunity against JE using MBV.
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